104 related articles for article (PubMed ID: 17591801)
1. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
Adamo V; Franchina T; Adamo B; Ferraro G; Rossello R; Maugeri Saccà M; Scibilia C; Valerio MR; Russo A
Ann Oncol; 2007 Jun; 18 Suppl 6():vi11-5. PubMed ID: 17591801
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
7. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
10. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.
Bartsch R; Wenzel C; Hussian D; Pluschnig U; Sevelda U; Koestler W; Altorjai G; Locker GJ; Mader R; Zielinski CC; Steger GG
BMC Cancer; 2006 Mar; 6():63. PubMed ID: 16539726
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
Tryfonidis K; Marreaud S; Khaled H; De Valk B; Vermorken J; Welnicka-Jaskiewicz M; Aalders K; Bartlett JMS; Biganzoli L; Bogaerts J; Cameron D;
Breast Cancer Res Treat; 2017 Jun; 163(3):507-515. PubMed ID: 28324265
[TBL] [Abstract][Full Text] [Related]
12. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
[TBL] [Abstract][Full Text] [Related]
14. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Tripathy D; Seidman A; Keefe D; Hudis C; Paton V; Lieberman G
Clin Breast Cancer; 2004 Oct; 5(4):293-8. PubMed ID: 15507176
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Extra JM; Antoine EC; Vincent-Salomon A; Delozier T; Kerbrat P; Bethune-Volters A; Guastalla JP; Spielmann M; Mauriac L; Misset JL; Serin D; Campone M; Hebert C; Remblier C; Bergougnoux L; Campana F; Namer M
Oncologist; 2010; 15(8):799-809. PubMed ID: 20671105
[TBL] [Abstract][Full Text] [Related]
17. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients.
Lunardi G; Vannozzi MO; Bighin C; Del Mastro L; Stevani I; Schettini G; Venturini M
Ann Oncol; 2003 Aug; 14(8):1222-6. PubMed ID: 12881383
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
20. Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Seiler M; Ray-Coquard I; Melichar B; Yardley DA; Wang RX; Dodion PF; Lee MA
Clin Breast Cancer; 2015 Feb; 15(1):60-5. PubMed ID: 25239224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
